Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis BioSpaceUCB's Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie's Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.Immunology & InflammationRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GHO, CBC merge to create largest healthcare investment firmNext: Parabilis follows hefty Regeneron deal with IPO push Related Stories Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026 Clinical Data ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data pharminent June 9, 2026 Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes pharminent June 9, 2026
